Publications by authors named "Isabel Sevilla"

Claim this Profile
C
Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914).
Jaume Capdevila, Jorge Hernando, Javier Molina-Cerrillo, Marta Benavent Viñuales, Rocio Garcia-Carbonero, Isabel Sevilla

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of tumor location and gene expression profile in sporadic desmoid tumor.
Jaime Carrillo-García, Nadia Hindi, Magda Conceicao, María Ángeles Sala, Aitziber Ugalde, Isabel Sevilla

Eur J Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab plus platinum-doublet chemotherapy in treatment-naive patients with advanced grade 3 Neuroendocrine Neoplasms of gastroenteropancreatic or unknown origin: The multicenter phase 2 NICE-NEC trial (GETNE-T1913).
Maria Carmen Riesco-Martinez, Jaume Capdevila, Vicente Alonso, Paula Jimenez-Fonseca, Alex Teule, Isabel Sevilla

Nat Commun· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/ CDKN2A.
Javier Martin-Broto, Jeronimo Martinez-Garcia, David S Moura, Andres Redondo, Antonio Gutierrez, Isabel Sevilla

Signal Transduct Target Ther· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022).
César Serrano, Rosa Álvarez, Juan Antonio Carrasco, Gloria Marquina, Jerónimo Martínez-García, Isabel Sevilla

Clin Transl Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS).
Jose Alejandro Pérez-Fidalgo, Eugenia Ortega, Jordi Ponce, Andres Redondo, Isabel Sevilla

Ther Adv Med Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial.
Enrique Grande, Cristina Rodriguez-Antona, Carlos López, Teresa Alonso-Gordoa, Marta Benavent, Isabel Sevilla

Oncologist· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509).
Jaume Capdevila, Nicola Fazio, Carlos Lopez, Alexandre Teulé, Juan W Valle, Isabel Sevilla

J Clin Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Thierry Andre, Mayur Amonkar, Josephine M Norquist, Kai-Keen Shiu, Tae Won Kim, Isabel Sevilla

Lancet Oncol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study.
Javier Martínez-Trufero, Luis Miguel De Sande-González, Pablo Luna, Javier Martin-Broto, Rosa Álvarez, Isabel Sevilla

Cancers (Basel)· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus.
Antonio Viúdez, Guillermo Crespo, María Luisa Gómez Dorronsoro, Imanol Arozarena, Juan Jesús Marín-Méndez, Isabel Sevilla

Pancreatology· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physician-perceived utility of the EORTC QLQ-GINET21 questionnaire in the treatment of patients with gastrointestinal neuroendocrine tumours: a multicentre, cross-sectional survey (QUALINETS).
Marta Benavent, Javier Sastre, Ignacio García Escobar, Angel Segura, Jaume Capdevila, Isabel Sevilla

Health Qual Life Outcomes· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02).
Jaime Feliu, Rocio Garcia-Carbonero, Jaume Capdevila, Inmaculada Guasch, Vicente Alonso-Orduna, Isabel Sevilla

Cancer Med· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression and Prognostic Value of Oestrogen Receptor Beta in Colorectal Cancer.
Elisabeth Pérez-Ruiz, Antonio Rueda, Lidia Pérez, Francisco Rivas-Ruiz, Esperanza Torres, Isabel Sevilla

Pathol Oncol Res· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Barbara Nuñez-Valdovinos, Alberto Carmona-Bayonas, Paula Jimenez-Fonseca, Jaume Capdevila, Ángel Castaño-Pascual, Isabel Sevilla

Oncologist· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients.
David S Moura, Rafael Ramos, Antonio Fernandez-Serra, Teresa Serrano, Julia Cruz, Isabel Sevilla

Oncotarget· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma.
Fernando Rivera, Meinolf Karthaus, J Randolph Hecht, Isabel Sevilla, Frédéric Forget

Int J Colorectal Dis· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience.
Guillermo Crespo, Paula Jiménez-Fonseca, Ana Custodio, Carlos López, Alberto Carmona-Bayonas, Isabel Sevilla

Future Oncol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program.
Isabel Sevilla, Ángel Segura, Jaume Capdevila, Carlos López, Rocío García-Carbonero

BMC Cancer· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study.
Javier Martin-Broto, Antonio López Pousa, Ramón de Las Peñas, Xavier García Del Muro, Antonio Gutierrez, Isabel Sevilla

J Clin Oncol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phosphorylated-insulin growth factor I receptor (p-IGF1R) and metalloproteinase-3 (MMP3) expression in advanced gastrointestinal stromal tumors (GIST). A GEIS 19 study.
Joan Maurel, Antonio López-Pousa, Silvia Calabuig, Silvia Bagué, Xavier Garcia Del Muro, Isabel Sevilla

Clin Sarcoma Res· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development.
Rocio Garcia-Carbonero, Roberto Garcia-Figueiras, Alberto Carmona-Bayonas, Isabel Sevilla, Alex Teule

Cancer Metastasis Rev· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS).
Jordi Rubió-Casadevall, Javier Martinez-Trufero, Xabier Garcia-Albeniz, Silvia Calabuig, Antonio Lopez-Pousa, Isabel Sevilla

Ann Surg Oncol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis.
Jaume Capdevila, Isabel Sevilla, Vicente Alonso, Luís Antón Aparicio, Paula Jiménez Fonseca

BMC Cancer· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer.
Sonia Molina-Pinelo, Amancio Carnero, Fernando Rivera, Purificacion Estevez-Garcia, Juan Manuel Bozada, Isabel Sevilla

BMC Cancer· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis